Has pharmacogenomics arrived?

The FDA yesterday linkurl:updated the label;http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html on a widely used blood thinner, warfarin, to include information about how a patient's genes will linkurl:predict response;http://www.the-scientist.com/article/display/14864/ to the drug. Patients with certain genetic variations should receive a lower dose of the drug, according to the added text. Although a handful of drugs already note such genetic information on their labels, most of these are

By | August 17, 2007

The FDA yesterday linkurl:updated the label;http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html on a widely used blood thinner, warfarin, to include information about how a patient's genes will linkurl:predict response;http://www.the-scientist.com/article/display/14864/ to the drug. Patients with certain genetic variations should receive a lower dose of the drug, according to the added text. Although a handful of drugs already note such genetic information on their labels, most of these are cancer drugs, which are used by a well-circumscribed set of patients. Warfarin is much more widely prescribed - about two million people start taking it each year, according to the FDA press release. Although the drug is notorious for its dosing difficulties, it has been around for more than 50 years, and doctors are used to managing dosing by trial and error. Though FDA commissioner Andrew C. von Eschenbach in the agency's statement calls the label change "one step in the FDA's commitment to linkurl:personalized medicine;http://www.the-scientist.com/article/display/18849/ ," what exactly doctors and patients are supposed to do with this genetic information is not entirely clear. A front-page linkurl:article;http://online.wsj.com/article/SB118722561330199147.html in the Wall Street Journal yesterday noted that although genetic tests can identify who has certain genetic variants, researchers have heatedly debated whether enough is known about these variations to determine what they mean for the patient. One clinical researcher quoted in the article, linkurl:Ann Wittkowsky;http://www.thrombosisclinic.com/en/11/84/373/ of the University of Washington, said that "It would be irresponsible and potentially harmful to suggest that testing be used, or even mentioned, in the label," adding that the testing is "fascinating science, but it is not yet ready for prime time."

Popular Now

  1. Henrietta Lacks’s Family Seeks Compensation
  2. Broad Wins CRISPR Patent Interference Case
    Daily News Broad Wins CRISPR Patent Interference Case

    The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.

  3. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  4. Abundant Sequence Errors in Public Databases
Business Birmingham